Sodium Diclofenac

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Reversible: no

Primary TargetCOX-1

Product does not compete with ATP.

Cell permeable: yes

Target IC₅₀: 60 nM and 200 nM for ovine COX-1 and COX-2 respectively; 9.5 µM against liver phenol sulfotransferase activity

General description

A cell-permeable, non-selective cyclooxygenase inhibitor (IC₅₀ = 60 nM and 200 nM for ovine COX-1 and COX-2 respectively) and potent non-steroidal anti-inflammatory drug with analgesic activity. Strongly inhibits insoluble transthyretin (TTR) amyloid fibril formation. Also inhibits liver phenol sulfotransferase activity (IC₅₀ = 9.5 µM).

A potent non-steroidal anti-inflammatory drug that inhibits both COX-1 (IC₅₀ = 76 nM) and COX-2 (IC₅₀ = 26 nM) activities. Also inhibits liver phenol sulfotransferase activity (IC₅₀ ~9.5 µM). Strongly inhibits insoluble transthyretin (TTR) amyloid fibril formation.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Kato, M., et al. 2001. J. Pharm. Pharmacol.53, 1679.Klabunde, T., et al. 2000. Nat. Struct. Biol.7, 312.Vietri, M., et al. 2000. Eur J. Clin. Pharmacol. 56, 81.Merlos, M., et al. 1996. Inflamm. Res.45, 20.Goa, K.L., and Chrisp, P. 1992. Drugs Aging 2, 473.Kurowski, M., and Dunky, A. 1992. Int. J. Clin. Pharmacol. Ther. Toxicol. 30, 479.

Reconstitution

Following reconstitution aliquot and freeze at -20°C. Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Toxic & Carcinogenic / Teratogenic (G)